Here’s what you should know:
1. Allergan is studying the drug’s safety and efficacy in patients with Crohn’s disease and ulcerative colitis. Allergan is also studying how biomarkers predict treatment response.
2. Allergan is launching the studies after a phase 2 clinical trial showed brazikumab had higher anti-inflammatory response and remission rates in patients with high levels of a “key” IBD biomarker.
3. Allergan will enroll 1,140 patients in its Crohn’s disease trial starting in December. Allergan is currently enrolling up to 375 patients in its ulcerative colitis trial.
4. Allergan Chief Research and Development Officer David Nicholson said, “These programs are part of our growing focus in gastroenterology, which will become even more significant for Allergan in the coming years.”
More articles on gastroenterology:
Drs. Steven Matulis, Douglas Morgan, & more: 6 GI physicians making headlines
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Vizinet awards 5 Ambulatory Care Quality and Accountability awards — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.